|Day's Range||75.27 - 75.64|
|52 Week Range||65.96 - 76.75|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.14%|
In 1Q17, Amgen’s (AMGN) Blincyto reported revenues of ~$34 million, which is equivalent to year-over-year sales growth of 26%.
On May 19, BD was trading at $184.13, as compared to its 50-day moving average of $183.37 and its 200-day moving average of $176.94.
Merck’s 1Q17 revenues were mainly driven by Gardasil, Keytruda, Proquad/Varivax, and its animal health products.